COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY

被引：0
|
作者：
Olivier, Kara [1 ]
Tombal, Betrand [2 ]
Thiele, Silke [3 ]
Li, Rui [4 ]
Joensuu, Heikki [5 ]
Smith, Matthew [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Clin Univ St Luc, Brussels, Belgium
[3] Bayer AG, Berlin, Germany
[4] Bayer HealthCare Inc, Whippany, NJ USA
[5] Orion Pharma, Espoo, Finland
来源：
ONCOLOGY NURSING FORUM | 2022年 / 49卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P386
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS
    Shore, Neal D.
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke
    Tutrone, Ronald
    Belkoff, Laurence
    Kapur, Shivani
    Jhaveri, Jay
    Srinivasan, Shankar
    Joensuu, Heikki
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2023, 209 : E380 - E380
  • [22] Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
    Saad, F.
    Vjaters, E.
    Shore, N. D.
    Olmos, D.
    Xing, N.
    Gomes, A. J. P. D. S.
    Mota, A. C. A.
    Salman, P.
    Jievaltas, M.
    Ulys, A.
    Jakubovskis, M.
    Kopyltsov, E.
    Han, W.
    Nevalaita, L.
    Testa, I.
    Le Berre, M-A.
    Kuss, I.
    Kunhiparambath, H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1257 - 1258
  • [23] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
  • [24] Efficacy and Safety of Darolutamide (DARO) in Combination with Androgen-Deprivation Therapy (ADT) and Docetaxel (DOC) by Disease Volume and Risk in the Phase 3 ARASENS Study
    Hussain, Maha
    Boegemann, Martin
    Tombal, Bertrand
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Shore, Neal
    Kopyltsov, Evgeny
    Kalebasty, Arash Rezazadeh
    Ye, Dingwei
    Cruz, Felipe Jose
    Suzuki, Hiroyoshi
    Srinivasan, Shankar
    Verholen, Frank
    Kuss, Iris
    Joensuu, Heikki
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 80
  • [25] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Montesa-Pino, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe
    Tammela, Teuvo L. J.
    Suzuki, Hiroyoshi
    Utriainen, Tapio
    Fu, Cheng
    Uemura, Motohide
    Mendez-Vidal, Maria J.
    Maughan, Benjamin L.
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
  • [26] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
  • [27] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [28] Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial
    Shore, Neal D.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Tombal, Bertrand
    Nordquist, Luke
    Cookson, Michael
    Jhaveri, Jay
    Thiele, Silke
    Srinivasan, Shankar
    Ortiz, Jorge
    Smith, Matthew R.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (01) : 218 - 219
  • [29] Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Manarite, Jan
    Muslin, David
    Farrington, Thomas
    Tombal, Bertrand
    FUTURE ONCOLOGY, 2022, 18 (21) : 2585 - 2597
  • [30] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
12345